Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SC599
- Development stage
- Phase 2
- Lead developer
- Institut Pasteur
- Modality
- Live Attenuated Vaccines → Live Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Oral
01
Overview
SC599 is a live attenuated vaccine candidate developed for the prevention of shigellosis, specifically targeting *Shigella dysenteriae* type 1. It was engineered by deleting key virulence and survival genes (virG/icsA, ent, and fep) from a wild-type *S. dysenteriae* 1 strain to reduce pathogenicity while retaining immunogenicity. The vaccine was developed by the Pasteur Institute and advanced to early-phase clinical trials as an oral monovalent live attenuated vaccine. Its mechanism of action is immunostimulation—eliciting an immune response against Shigella infection. Development has been discontinued after phase 1 clinical evaluation.
- Other names
- SC599 oral vaccineSC-599 oral vaccineSC 599 oral vaccinelive attenuated Shigella dysenteriae 1 vaccine
Beyond the preview
Go deeper on SC599.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SC599.